Why a new textbook matters if you are weighing up joint surgery

If your consultant has put you on a 'watch and wait' pathway — perhaps physio, pain management, and a review in six months — it is worth knowing that the clinical conversation around joint care has shifted considerably in recent years. That shift has now been codified in a single, substantial volume.

Musculoskeletal Regeneration Medicine: Regenerative Medicine Across AI, Engineering, and Clinical Orthopaedics, edited by Professor Paul Lee and published by Springer Nature in 2025, draws together orthopaedic surgeons, scientists, and engineers around a shared clinical thesis: that joint care is moving away from mechanical replacement and towards biological repair. Its multi-disciplinary authorship gives it weight as a current consensus document — not a single researcher's perspective, but a convergence of specialisms that rarely occupy the same page.

For patients in Lincolnshire and across the UK currently deciding between continued conservative care and surgical escalation, the practical implication is this: earlier biological intervention may, in some cases, reduce or prevent the need for joint replacement altogether. That argument is made explicitly within the textbook.

What follows is a plain-language account of the evidence it presents — not a claim that all of these treatments are available or suitable today, but a clear map of where joint care is heading and what questions a consultant assessment might now reasonably explore.

From symptom control to biological repair — the core shift

Think of the traditional approach to a deteriorating joint as managing a leaky roof with buckets — effective at limiting immediate damage, but leaving the underlying structure unchanged. Pain relief, anti-inflammatory injections, and physiotherapy have long been the standard toolkit, with joint replacement surgery waiting at the end of the line when the structure finally fails. The textbook's central argument is that this binary — manage symptoms or replace the joint — is being replaced by a third category: repair the biological material itself.

The therapies that make up this emerging category operate at different levels of the body's own repair systems. Platelet-Rich Plasma (PRP) concentrates the patient's own growth signals to encourage tissue healing. Extracellular Matrix (ECM) biologics work with the structural scaffolding that supports cartilage cells. Stem cell technologies introduce regenerative cells capable, in principle, of differentiating into joint tissue. Photo-biomodulation uses light energy to stimulate cellular metabolism. Growth factor injections target specific molecular signals involved in tissue repair. Gene therapies — still at an early stage of clinical translation — aim to address osteoarthritis at the molecular level, with some researchers describing the goal as shifting it from a condition that is managed to one that may be modified.

These approaches are not interchangeable, and the textbook is careful not to present them as equivalent. Each sits at a different point on the spectrum of joint deterioration, with varying levels of clinical evidence behind it. What unites them is the underlying ambition: a coordinated biological strategy aimed at restoring tissue rather than masking damage. The practical implication is that the question a consultant asks today may no longer be simply 'how long can we delay replacement?' but rather 'which biological tools, applied in which order, give this joint the best chance of genuine repair?'

The four pillars — why physics, chemistry, biology, and time all count

Underlying the textbook's clinical argument is a structural framework that explains why no single injection or procedure works in isolation. Professor Paul Lee organises musculoskeletal regeneration around four pillars — Physics, Chemistry, Biology, and Time — and the logic of each has direct implications for patients deciding when and how to act.

Physics concerns alignment and load. If a knee tracks slightly inward with every step, the cartilage on its inner surface absorbs disproportionate force, and that mechanical pattern continues regardless of what is injected into the joint. Biologics introduced into a poorly aligned joint are, in effect, working against the forces still damaging it. Correcting biomechanics — through gait analysis, bracing, or targeted rehabilitation — is therefore a prerequisite, not an afterthought. Tools such as MAI Motion® (a UKCA/MHRA-registered markerless motion-capture system) can translate these patterns into objective, repeatable measurements that inform treatment planning.

Chemistry covers the biological environment that regenerative inputs enter. PRP, ECM scaffolds, and stem cell therapies perform differently depending on inflammation levels, metabolic health, and the molecular milieu of the joint at the time of treatment.

Biology reflects the tissue's own regenerative capacity. Earlier-stage damage, younger tissue, and good systemic health all amplify what therapies can achieve. This is not a reason for fatalism at later stages, but it does support the case for earlier assessment.

Time is perhaps the most patient-relevant pillar. Small mechanical and biological misalignments do not stay small — they compound over months and years. Waiting until symptoms become severe may narrow the window in which repair-oriented strategies are most effective. Acting earlier, even without dramatic symptoms, may preserve more options.

The textbook also names sleep, psychology, and rehabilitation as active ingredients in MSK repair — not lifestyle add-ons, but factors that measurably influence tissue recovery and pain processing. This broadens the clinician's toolkit and, equally, broadens what patients can contribute to their own outcomes.

AI in MSK medicine — what it actually does in a consultation

Two radiologists reviewing the same MRI scan may genuinely reach different conclusions — not because one is wrong, but because interpreting joint tissue in greyscale images involves pattern recognition that varies between readers and between sessions. This is not a theoretical concern; it is a documented feature of conventional imaging practice, and it matters to any patient trying to track whether their joint is genuinely improving or slowly worsening.

The textbook edited by Professor Paul Lee frames AI — computer vision, deep learning, machine learning — not as an approaching horizon but as a set of analytical tools that MSK clinicians can begin deploying now. Where human review naturally focuses on what is most prominent, AI processes the full imaging dataset across scans: detecting subtle cartilage thinning, flagging asymmetries in joint loading, and quantifying changes that might otherwise be read as normal variation. The aim is a more reproducible diagnostic picture — one that informs personalised treatment planning rather than overriding clinical judgement.

In practice at our own clinics, this direction is already operational. onMRI™ (an AI-driven MRI analysis platform, patent-pending) applies quantitative cartilage segmentation to improve consistency between scans and readers. MAI Motion® — already introduced in the context of biomechanical assessment — captures movement data with objective, repeatable precision. Mentioned together here not as a product showcase but because they illustrate a broader point: the textbook's argument about AI-enhanced clinical decision-making is not purely theoretical; at some centres, it already shapes how a consultation runs.

What has solid evidence behind it — and what is still being developed

Calibrating expectations matters as much as understanding the science. Not every therapy described in this textbook sits at the same stage of clinical development, and a clear picture of where the evidence stands helps patients ask better questions at consultation.

Established, with systematic-review-level evidence. Intra-articular mesenchymal stem cell (MSC) injections for knee osteoarthritis have been evaluated in multiple systematic reviews and meta-analyses, with consistent findings of cartilage repair and clinical benefit. Bone marrow concentrate injections have a comparable evidence trajectory, from preclinical work through to early clinical studies. Platelet-Rich Plasma (PRP) has a growing body of clinical evidence in early-stage joint degeneration. These are not experimental offerings — they are the current front line of biologic joint care.

Promising, with early or emerging evidence. Smart biomaterial scaffolds, extracellular vesicles, and 3D-bioprinted patient-specific implants — including commercialising products such as Nanochon — are advancing through clinical trials for knee and hip repair as of 2026. Vascularisation and long-term mechanical performance remain technical challenges that trials are actively working to resolve.

Research stage, not yet in mainstream clinical use. Genome engineering for osteoarthritis — including CRISPR-based editing and intra-articular gene delivery — is under active translational investigation, with the aim of creating disease-modifying rather than symptom-managing treatments. It is not currently available as a clinical therapy.

One caveat applies across all tiers: there is currently no cure for osteoarthritis. Regenerative approaches can slow progression, reduce symptoms, and in some cases support meaningful tissue repair — but patients should approach any treatment in that frame, not in the expectation of reversal.

Access to even well-evidenced therapies is not guaranteed. Regulatory approval timelines, cost, and equity of access mean that laboratory success does not translate automatically into patient availability. The US ARPA-H NITRO programme — a federal initiative specifically targeting the elimination of osteoarthritis — signals that this gap is a recognised policy priority, not an oversight.

Where your joint might sit on the regeneration pathway

Staging matters. MSK Doctors applies a three-stage model — Regenerate, Repair, Replace — to make the clinical decision boundaries explicit: not every joint needs a biologic intervention, and not every joint that has moved beyond biological repair requires immediate replacement. Where a joint sits on that spectrum depends on the degree of tissue loss, the patient's age and loading patterns, and, critically, how early the assessment takes place.

Early cartilage changes without bone loss are generally within the regenerative window, where the therapies described across this article are most likely to be relevant. Bone-on-bone, end-stage disease is a different clinical territory where replacement may remain the right path. The boundary between them is not fixed — it depends on individual assessment, and it shifts depending on biomechanics, biology, and time, which is precisely why the textbook's four-pillar framework treats those variables as inseparable. Objective measurement changes the quality of the conversation a patient can have with any clinician.

For patients in Lincolnshire and the wider non-London catchment, the MSK Doctors Sleaford Regeneration Hub is where this clinical direction is applied in practice; the Grantham MFO Life Sciences Lab is where the underlying research is being developed. Both are accessible without GP referral at mskdoctors.com.

What this body of evidence ultimately shifts is not the list of available procedures but the timing of the conversation about them. Three questions are worth raising at any orthopaedic consultation: Am I still within a regenerative window, or have I passed it? What would objective assessment of my joint loading and cartilage condition show? And is my current trajectory moving towards replacement — or is there a point, earlier than surgery, at which targeted intervention could change that course?

1. [1] Articular cartilage repair biomaterials: strategies and applications. (2024). https://doi.org/10.1016/j.mtbio.2024.100948 https://doi.org/10.1016/j.mtbio.2024.100948
2. [2] Hyperplastic Human Macromass Cartilage for Joint Regeneration. (2023). https://doi.org/10.1002/advs.202301833 https://doi.org/10.1002/advs.202301833
3. [3] 3D-bioprinting for joint regeneration. (2026). https://doi.org/10.3389/fbioe.2026.1742269 https://doi.org/10.3389/fbioe.2026.1742269
4. [4] Cartilage Integrity: A Review of Mechanical and Frictional Properties and Repair Approaches in Osteoarthritis. (2024). https://doi.org/10.3390/healthcare12161648 https://doi.org/10.3390/healthcare12161648